TWIST1 GENE EXPRESSION AS A BIOMARKER FOR
PREDICTING PRIMARY DOXORUBICIN RESISTANCE
IN BREAST CANCER
Demir S1,10,*, Müslümanoğlu MH2, Müslümanoğlu M3, Başaran S4,
Çalay ZZ5, Aydıner A6, Vogt U7, Çakır T8, Kadıoğlu H9, Artan S1
*Corresponding Author: Selma Demir, Ph.D., Trakya University Faculty of Medicine, Department of
Medical Genetics, 22030 Iskender, Edirne, Turkey. Tel: +90(284)2357642/2330. Fax: +90(284)2357652.
E-mail: selmaulusal@trakya.edu.tr
page: 25
download article in pdf format
|
|
Abstract
Doxorubicin is one of the most commonly used chemotherapeutic
agents for adjuvant chemotherapy of breast
cancer. In the studies focused on finding biomarkers to
predict the response of the patients and tumors to the drugs
used, the Twist transcription factor has been suggested as
a candidate biomarker for predicting chemo-resistance of
breast tumors. In this study, we aimed to investigate the relationship
between TWIST transcription factor expression
and the effectiveness of doxorubicin treatment on directly
taken primary tumor samples from chemotherapy-naive
breast cancer patients. Twenty-six primary breast tumor
samples taken from 26 different breast cancer patients
were included in this study. Adenosine triphosphate tumor
chemo-sensitivity assay (ATP-TCA) has been used
to determine tumor response to doxorubicin and real-time
reverse-transcription polymerase chain reaction (RT-PCR)
was used for analyzing the TWIST1 gene expression of
tumors. There was a significant difference in TWIST gene
expression between responder and non responder tumors (p
<0.05). The TWIST gene expression of the drug-resistant
group was higher than the responsive group. This difference
was not dependent on the histopathological features
of tumors. In conclusion, compatible with earlier studies
that have been performed with cell lines, the current study
supports the role of higher TWIST gene expression as a
biomarker for predicting the response of breast tumors to
chemo-therapeutic agent doxorubicin.
|
|
|
|
 |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
|
